NOVERA COMPOUNDS

Tirzepatide 10mg

Tirzepatide is a synthetic dual incretin peptide designed to mimic GLP-1 and GIP activity in metabolic research models. It has been studied for its effects on...

Tirzepatide is a synthetic dual incretin peptide designed to mimic GLP-1 and GIP activity in metabolic research models. It has been studied for its effects on glucose regulation, appetite control, and energy balance, with observed impacts on body weight and metabolic markers in preclinical and clinical investigations.

10% off, code: PEPTEN
Purity Guarantee

Tirzepatide 10mg

Sign in to view pricing and purchase this product.

Log In Sign Up
Quantity Discount (%) Price
1 - 5 — $135.00
6 - 10 9.63 % $122.00
11 - 20 18.52 % $110.00
21+ 26.67 % $99.00

Why choose Novera Compounds peptides

Research-grade Quality

Every compound is manufactured to research-grade standards and intended strictly for laboratory and research use. Consistent quality you can build a reproducible protocol around.

Documented and traceable

  • Batch number on every vial

  • Published Certificates of Analysis

  • Purity verified by third-party testing

Handled and shipped with care

Temperature-sensitive compounds are stored and shipped under controlled conditions, so material arrives in the state your research requires. Expert support on hand at every step.

About the product

Tirzepatide is a synthetic, long-chain peptide designed to model the activity of incretin-related compounds in research settings. Classified as a dual-acting GLP-1/GIP peptide, it features a modified amino acid sequence that supports stability and consistency in controlled studies. This compound has a molecular weight of approximately 4813.48 g/mol and is typically supplied as a high-purity lyophilized powder in a 10mg vial.

Tirzepatide is used in research to explore its role in metabolic signaling and glucose-related processes. It is commonly employed in laboratory environments to examine how peptide-based compounds interact with endocrine and metabolic systems.

Tirzepatide (10mg) Key Features & Specs

  • Subcategory: Weight Loss & Metabolic Peptides
  • Strength: 10 mg
  • CAS: 2023788-19-2
  • Chemical Formula: C₂₂₅H₃₄₈N₄₈O₆₈
  • Molecular Weight: 4813.48 g/mol
  • Peptide Sequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys(C20-linker)-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
  • Synonyms: P1206, LY3298176, tirzepatida, tirzepatidum, OYN3CCI6QE

For laboratory research use only.

Tirzepatide (10mg) Research Uses

Tirzepatide is being studied for its role in metabolic and endocrine processes. It has been explored for its interaction with glucose regulation, insulin signaling, and energy balance mechanisms.

Ongoing research also focuses on how this peptide may influence appetite-related signaling and coordinated metabolic responses. It is used to better understand how dual-acting peptides behave across multiple biological systems in controlled environments.

Tirzepatide (10mg) Insights & Observed Findings

Data from Tirzepatide research include observations from in vitro and preclinical models, in which varying concentrations are applied based on the study design. Reported ranges vary depending on experimental goals and biological conditions.

Studies have examined its activity, particularly regarding metabolic signaling pathways and glucose-related processes. These findings are limited to laboratory investigations and should not be interpreted as clinical outcomes.

Tirzepatide (10mg) Handling & Storage

Store Tirzepatide (10mg) at –20°C in a controlled laboratory environment, protected from light, heat, and moisture to preserve its integrity.

Once reconstituted, store the solution refrigerated and follow appropriate laboratory protocols. To maintain consistency, avoid repeated freeze-thaw cycles.

Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 156588324, Tirzepatide. https://pubchem.ncbi.nlm.nih.gov/compound/156588324
  2. Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. Published 2020 Sep 3. doi:10.1172/jci.insight.140532
  3. Sun B, Willard FS, Feng D, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci U S A. 2022;119(13):e2116506119. doi:10.1073/pnas.2116506119
  4. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009
  5. Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022;27(13):4315. Published 2022 Jul 5. doi:10.3390/molecules27134315